Hematólogo en Guadalajara - Dr Jorge Lozano Valdivia

02/10/2025

15/06/2025

12/12/2024

ASH 2024

21/06/2024

Today’s EHA is on the diagnostic workup of unexplained , clonal cytopenia of undetermined significance and idiopathic cytopenia of undetermined significance .

Can you fill in A, B & C? Share your answers below or come back tomorrow for the answer.

Interested in ? Listen to our podcast featuring Prof Helen Papadaki (University of Crete, Greece), who discusses the link between clonal hematopoiesis and the risk of developing MDS or AML.

Find it on major podcast platforms or here on the : https://ehacampus.ehaweb.org/ilp/pages/mediacontent.jsf?mediaId=585569&catalogId=355089&menuId=1106&client=

What did you think of this microlearning experience? Help EHA by filling this one-minute survey: https://wkf.ms/3Pdq1uw ‏‎ ‎

14/06/2024

Hace falta sumar los esfuerzos en la sociedad para generar la cultura de donación de sangre voluntaria

18/05/2024

Recombinant ADAMS13 Treatment for Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (TTP) is a rare disease caused by a severe hereditary deficiency of ADAMS13, which normally cleaves von Willibrand factor (VWF). With the accumulation of multimers of VWF with high platelet-binding activity, congenital TTP often manifests as thrombocytopenia since platelets are consumed in forming micro-clots, which may lead to organ failure or even death. Standard treatment involves ADAMS13 replacement from donor-derived plasma and/or plasma products. In November 2023, recombinant ADAMS13 (rADAMS13) was approved by the US Food and Drug Administration for congenital TTP treatment; an encouraging interim analysis from a phase 3, multinational, open-label, crossover trial of rADAMS13 treatment was recently published. Briefly, 48 adults and children with congenital TTP were randomized 1:1 to receive either rADAMS13 or standard therapy as prophylaxis for the first 6-month block; in the second 6-month block, the randomization blocks were switched (i.e. crossed-over); and in the third 6-month block, all patients received rADAMS13. None of the patients receiving rADAMS13 had an acute TTP event compared to one event in a patient receiving standard therapy. On average, ADAMS13 activity returned to 100% normal levels under rADAMS13 therapy compared to 19% with standard therapy. In addition, 9% of patients experienced mild or moderate adverse events while receiving rADAMS13 compared to 48% with standard therapy. The risk of immunogenicity appears to be low, but 14 patients are continuing in the trial to continue to monitor the safety and efficacy of rADAMS13.
https://transfusionnews.com/2024/05/15/recombinant-adams13-treatment-for-congenital-thrombotic-thrombocytopenic-purpura/

10/04/2024

📚 New course out on and !

Learn about the overlapping characteristics of Ph-neg MPN & MDS, and other disorders. The course covers different perspectives, highlighting commonalities and differences with MPN and MDS.

Find it on : https://ehaedu.org/comm_diff_MDSMPN

04/11/2023

Welcome to EHA . Today's clinical schema focuses on . Can you fill in A, B and C?

Interested in ? See our recently published Hematology Update covering AML diagnosis and treatment on :
https://ehaedu.org/HU_AML_course

19/10/2023

Welcome to EHA . Today's clinical schema is on iron deficiency in older patients. Can you fill in A, B and C?

Interested in ? This schema is a sneak preview of our sponsored Iron Deficiency Program on : https://eha.fyi/ID_Prog